{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '7.4 STUDY WITHDRAWAL', 'Upon participant withdrawal from the study, all end of study evaluations and tests will be', 'conducted. All participants who discontinue due to an AE must be followed until the event resolves', 'or stabilizes. Appropriate medical care should be provided until signs and symptoms have abated,', 'stabilized, or until abnormal laboratory findings have returned to acceptable or pre-study limits.', \"The final status of the AE will be reported in the participant's medical records and the appropriate\", 'eCRF.', 'Reasons for study withdrawal should be classified as follows:', 'Death.', 'Progressive disease.', 'Treatment-related toxicity.', 'Toxicity unrelated to treatment.', 'Investigator judgment.', \"The Investigator may withdraw a participant if, in his/her judgment, it is in the participant's\", 'best interest to do so.', 'Participant receives an additional adjuvant therapy.', 'Noncompliance', 'Participant voluntary withdrawal', 'A participant may withdraw from the study at any time, for any reason. If a participant', 'discontinues treatment, an attempt should be made to obtain information regarding the', 'reason for withdrawal.', 'Participants in which the surgical pathology demonstrates perineural invasion,', 'extracapsular spread or the participant requires additional therapy including radiation or', 'chemotherapy.', 'Participants who are unavailable for follow-up evaluations should be classified as lost to follow-', 'up for 1 of the following reasons:', 'Lost to follow-up: For a participant to be considered lost to follow-up, the investigator must', 'make two attempts to re-establish contact with the participant. The attempts to re-establish', 'participant contact must be documented (e.g., certified letter).', 'Death: Date and cause of death will be recorded for those participants who die within', '30 days after last dose of study drug (telephone contact with family is acceptable).', '8', 'STUDY PROCEDURES', 'Unless otherwise defined in the written protocol text, all pprocedures/assessments will be conducted', 'in accordance with RPCI Clinical Research Services Standard Operating Procedures.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 26 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '8.1', 'PARTICIPANT RANDOMIZATION AND REGISTRATION', 'We will employ a web-based stratified blocked randomization scheme developed at RPCI by the', 'biostatistician in conjunction with the GOG Foundation Statistical & Data Management Center.', 'Participants will be randomized stratified by study site with permuted blocks of size 4 within strata', 'and will assigned to standard of care surgery or PDT with HPPH. Study sites will need to have', 'IRB approval entered into the system prior to accessing the randomization system. Eligibility of', 'each participant will be established prior to randomization.', 'Informed consent MUST be completed prior to receiving any study related procedures.', '8.2 BASELINE EVALUATIONS', 'The following will be performed within 1 to 45 days prior to administration of study drug or', 'surgery:', 'History, physical', 'Clinical examination with photograph of lesion if possible.', 'Confirm tumor staging with CT or MRI scans of the head and neck and chest.', 'Vital signs (i.e., temperature, heart rate, respiratory rate, blood pressure, body weight, and', 'height)', 'Hematology [(i.e., complete blood count (CBC) with automated differential]: WBC, RBC,', 'HGB, HCT, platelet, MCV, MCH, MCHC, % neutrophils, absolute neutrophils, %', 'monocytes, absolute monocytes, % eosinophils, absolute eosinophils, % basophils,', 'absolute basophils, % lymphocyte, absolute lymphocyte, platelet confirmation (as', 'clinically indicated), and differential confirmation (as clinically indicated)', 'Chemistry (i.e., complete metabolic panel (CMP): chloride, CO2, potassium, sodium,', 'BUN, glucose, calcium, creatinine, total protein, albumin, total bilirubin, alkaline', 'phosphatase, AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap)', 'Biopsy (diagnosis)', 'HCG urine or serum for women of childbearing potential', 'Performance status (ECOG): Appendix D', 'Evaluate lesion size', 'Quality of Life Questionnaire: Appendix H', '8.3', 'DAY 0 INFUSION (ARM 2 - PDT WITH HPPH)', 'Vital signs (i.e., temperature, heart rate, respiratory rate, blood pressure, and body weight)', 'Correlative studies blood samples', 'HPPH infusion', 'Adverse events', '8.4', 'DAY 1 TREATMENT', 'Laser PDT with HPPH (Arm 2) or Surgery (Arm 1)', 'Vital signs (i.e., temperature, heart rate, respiratory rate, blood pressure, and body weight)', 'Optical spectroscopy (Arm 2)', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 27 of 64']\n\n###\n\n", "completion": "END"}